Critically Ill COVID-19 Patients Show Reduced Point of Care-Measured Butyrylcholinesterase Activity-A Prospective, Monocentric Observational Study.
COVID-19
butyrylcholinesterase
point of care testing
sepsis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
03 Sep 2022
03 Sep 2022
Historique:
received:
02
08
2022
revised:
29
08
2022
accepted:
02
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
A biomarker for risk stratification and disease severity assessment in SARS-CoV-2 infections has not yet been established. Point of care testing (POCT) of butyrylcholinesterase (BChE) enables early detection of systemic inflammatory responses and correlates with disease severity in sepsis and burns. In acute care or resource-limited settings, POCT facilitates rapid clinical decision making, a particularly beneficial aspect in the management of pandemic situations. In this prospective observational study, POCT-measured BChE activity was assessed in 52 critically ill COVID-19 patients within 24 h of ICU admission and on the third and seventh day after ICU admission. Forty (77%) of these patients required venovenous extracorporeal membrane oxygenation (vvECMO). In critically ill COVID-19 patients, BChE activity is significantly decreased compared with healthy subjects, but also compared with other inflammatory conditions such as sepsis, burns, or trauma. POCT BChE activity reflects the severity of organ dysfunction and allows prediction of 28-day mortality in critically ill COVID-19 patients. Implementing early POCT BChE measurement could facilitate risk stratification and support admission and transfer decisions in resource-limited settings.
Identifiants
pubmed: 36140551
pii: diagnostics12092150
doi: 10.3390/diagnostics12092150
pmc: PMC9498245
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Med Hypotheses. 2020 Nov;144:110274
pubmed: 33254578
Mediators Inflamm. 2015;2015:274607
pubmed: 25762852
J Intensive Care Med. 2017 Jun;32(5):346-352
pubmed: 26951579
Front Physiol. 2021 May 13;12:653985
pubmed: 34054572
Diagnostics (Basel). 2021 Nov 25;11(12):
pubmed: 34943438
Burns. 2021 Jun;47(4):863-872
pubmed: 33248805
Sci Rep. 2021 Jun 4;11(1):11886
pubmed: 34088975
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Front Pharmacol. 2020 Aug 06;11:1124
pubmed: 32848743
Mediators Inflamm. 2018 Apr 29;2018:1942193
pubmed: 29853783
Sci Rep. 2019 Jul 18;9(1):10437
pubmed: 31320703
Crit Care. 2014 Jan 30;18(1):R24
pubmed: 24479557
BMJ Evid Based Med. 2021 Jun;26(3):107-108
pubmed: 32934000
J Inflamm Res. 2016 Nov 18;9:221-230
pubmed: 27920568
J Cell Physiol. 2016 Sep;231(9):1862-9
pubmed: 26754950
Front Immunol. 2021 Feb 08;11:595342
pubmed: 33633726
J Mol Neurosci. 2014 Jul;53(3):298-305
pubmed: 24254221
Chest. 2022 Jun;161(6):1446-1448
pubmed: 35469670
Am J Pathol. 2021 Jan;191(1):4-17
pubmed: 32919977
Annu Rev Immunol. 2012;30:313-35
pubmed: 22224768
J Clin Med. 2021 May 11;10(10):
pubmed: 34064851
Pharmacol Ther. 2017 Nov;179:1-16
pubmed: 28529069
Chest. 2005 Dec;128(6):3937-54
pubmed: 16354866
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
J Thorac Dis. 2016 Mar;8(3):311-3
pubmed: 27076924
Neuroimmunomodulation. 2020;27(2):80-86
pubmed: 33341814
J Infect. 2021 Feb;82(2):282-327
pubmed: 32822684
Nat Rev Immunol. 2009 Jun;9(6):418-28
pubmed: 19461672
Crit Care. 2022 Jun 28;26(1):190
pubmed: 35765102
PLoS One. 2015 Jun 24;10(6):e0129082
pubmed: 26107885
ASAIO J. 2021 May 1;67(5):485-495
pubmed: 33657573
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
J Mol Med (Berl). 2007 Nov;85(11):1239-51
pubmed: 17657467